# Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

> **NCT03598725** · PHASE4 · UNKNOWN · sponsor: **Beijing Children's Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Hemophilia A With Inhibitor

## Interventions

- **DRUG:** Coagulation Factor VIII
- **DRUG:** Prednisone
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03598725
- **Lead sponsor:** Beijing Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598725, "Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03598725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*